BAXTER HEALTHCARE CORPORATION for BAXTER HEALTHCARE CORPORATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2009 | $980,000 | Replaced |
| 2nd Quarter - Report | Oct 20, 2009 | $1,070,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Trade issues with China
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH V SCHWAN | Deputy Chief of Staff, U.S. Dept of Commerce |
Taxation/Internal Revenue Code TAX
H.R. 1, American Recovery and Reinvestment Act of 2009, as it relates to the taxation of foreign earnings of U.S. multinational corporations. H. Con. Res. 85 and S. Con. Res. 13, setting forth the congressional budget for the U.S. Governoment for FY 2010, as it relates to the taxation for foreign earnings of U.S. multinational corporations. Issues related to the taxation of foreign earnings of U.S. multinational corporations
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH V SCHWAN | Deputy Chief of Staff, U.S. Dept of Commerce |
Copyright/Patent/Trademark CPT
S.515/H.R. 1260: Patent Reform Act of 2009
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CREVISTON | — |
| JED PERRY | — |
| JOSEPH V SCHWAN | Deputy Chief of Staff, U.S. Dept of Commerce |
Health Issues HCR
H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CREVISTON | — |
| JACK MANIKO | Counsel, House Cmte on Energy & Commerce |
| KELLI MILLS LESTER | — |
| JED PERRY | — |
| JOSEPH V SCHWAN | Deputy Chief of Staff, U.S. Dept of Commerce |
| DEBORAH WILLIAMS | Prof. Staff, House Committee on Ways & Means |
Medicare/Medicaid MMM
H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans. Drug and biological product pricing and reimbursement Product Payment Issues Therapy Payment Issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CREVISTON | — |
| JACK MANIKO | Counsel, House Cmte on Energy & Commerce |
| KELLI MILLS LESTER | — |
| JED PERRY | — |
| JOSEPH V SCHWAN | Deputy Chief of Staff, U.S. Dept of Commerce |
| DEBORAH WILLIAMS | Prof. Staff, House Committe on Ways & Means |
Labor Issues/Antitrust/Workplace LBR
H.R. 1409/S. 560: To amend the National Labor Relations Act to establish an efficient system to enable employees to form, join, or assist labor organizations, to provide for mandatory injunctions for unfair labor practices during the organizing efforts, and for other purposes
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH V SCHWAN | Deputy Chief of Staff, U.S. Dept of Commerce |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.